ライフサイエンスコーパス: be developed

1 Such localized models must also be developed even when the data required for characterizing l

2 We argue that regulation and mitigation should always be developed by looking at potential effects from the perspec

3 ogels can be used as a potential carrier for ADSCs, and can be developed as a potential therapeutic agent for treating OA

4 lactics against stress-induced depressive-like behavior can be developed in a sex-specific manner and demonstrate that ov

5 s indicate that sensitive and reliable LC-MS/MS methods can be developed for the targeted detection and quantification of

6 s from the coronavirus disease 2019 (COVID-19) pandemic can be developed into an immunologists' guide for preparedness fo

7 Because they can be developed to bind to many disease agents, antibodies can b

8 Capitalizing on this knowledge, novel diagnostic tools can be developed to guide clinical diagnosis of contact allergies

9 ndicate that Sarm1 and/or specific calpain inhibitors could be developed to prevent cisplatin induced peripheral neuropat

10 We believe this technique could be developed into powerful forensic tools to aid the attribut

11 ports the utility of this compound as a molecule that could be developed as an antinociceptive agent similar to morphine

12 the event that a broad spectrum exercise mimetic might ever be developed, we discuss some generic issues related to adopt

13 ogic mechanisms should exist and therapeutic approaches may be developed to balance between aging and tumor suppression,

14 We suggest ways the evidence base may be developed.

15 ovide insights into how novel small-molecule inhibitors may be developed to target specific subpopulations of Aurora A.

16 Overall, we indicated this new material may be developed as an anti-bacterial agent for prolonging the sh

17 during the shipment of raisins, a crystalline material may be developed on their surface, affecting the final acceptabil

18 tential nutritional, immune, and microbial therapeutics may be developed into promising future avenues of precision treat

19 BMDC adoptive transfer may be developed into a new approach that alleviates asthma by mo

20 Strategies to target PGE(2) might be developed for treatment of CRC.

21 Strategies to expand tuft cells might be developed for treatment of CD.

22 Strategies to target the PAF1-PHF5A-DDX3 complex might be developed to slow or inhibit progression of pancreatic can

23 Inhibitors of PVRL1/TIGIT, along with anti-PD1 might be developed for treatment of HCC.

24 es directed towards specific TLR2 signaling processes might be developed for treatment of colonic motility disorders rela

25 Strategies to increase the expression of RSPO1 might be developed for the treatment of intestinal adenomas.

26 This strategy might be developed for the treatment of celiac disease.

27 in cancer diagnosis and immunotherapy and could potentially be developed for vaccination and chemotherapy drug transporta

28 ACE2-Ig variants developed in this study could potentially be developed to protect from SARS-CoV-2 and some other SARS-l

29 ation regarding the threat from biological invasions should be developed, and that conservation practitioners should take

30 Measures should be developed that better characterize diversity and assess ef

31 e placed in shelters and those who are not, pathways should be developed to allow young adult males to enter accommodatio

32 Last, financial incentives and penalties should be developed or more actively reinforced.

33 Appropriate prevention and management strategies should be developed to reduce its impact.

34 However, data mining strategy should be developed for complete utilization of the large amount of

35 eting approach is a viable therapeutic strategy that should be developed further in pre-clinical studies.

36 , and tools requiring further research or those that should be developed.

37 n, as exemplified by an enzyme-resistant hydrogel, may thus be developed.

38 erogeneity is necessary if more effective treatments are to be developed.

39 we anticipate that newer device iterations will continue to be developed enhancing the current merits of these modalities

40 urthermore, our studies highlight the potential of ISG15 to be developed as a novel biotherapeutic molecule against FMD.I

41 structure-based efforts have identified promising leads to be developed as novel therapeutic agents for SCD.

42 very strategies that ensure durable bioavailability need to be developed to translate this concept into a clinically feas

43 e and accurate detection methods targeting antigens need to be developed urgently.

44 iac complications in this high-risk cohort of women need to be developed.

45 ion as inhibitors of filovirus entry, with the potential to be developed as therapeutic agents for the treatment and cont

46 This approach has considerable potential, in our view, to be developed into a therapeutic device suitable for use outsi

47 Selective ROS1 inhibitors have yet to be developed, and thus the specific adverse effects of ROS1 i

48 small-molecule orally available antiviral drugs have yet to be developed.

49 e a priority for immunisation should an efficacious vaccine be developed.

50 s) post-2020 global biodiversity framework and targets will be developed as we enter the last decade to meet the Sustaina